The two main resistance mechanisms are via gene amplification of the BCR-ABL fusion gene, which drives the CML, or a point mutation resulting in a modification to the target protein of imatinib. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.